Yellow fever
Yellow fever is a viral disease spread by infected mosquitoes, mainly in tropical parts of Africa and the Americas. The mosquitoes involved usually bite during the day. The virus circulates in forest environments and can spill over into people; mosquito-mediated spread in towns and cities is also a concern where vaccination coverage is low. Symptoms usually begin 3–6 days after infection. Early illness includes fever, headache, body aches, nausea and weakness. Many people improve, but about 15% of infected people develop severe disease, with yellowing of the skin and eyes, bleeding, organ failure or shock. WHO reports that about half of patients in this severe phase die. There is no established specific antiviral treatment; care focuses on hydration and managing complications. A single vaccine dose provides lifelong protection for most people, although some people need an individual medical assessment before vaccination. Outbreaks continued in Africa and the Americas in 2026. Vaccination, daytime mosquito-bite prevention, prompt testing and rapid outbreak response remain the main protections.
Key facts
| Transmission | Bites from infected, mainly day-biting Aedes, Haemagogus and Sabethes mosquitoes; forest mosquito–primate cycles can spill over into humans, with potential for mosquito-mediated urban spread. |
|---|---|
| Incubation | 3–6 days. |
| Case fatality | WHO reports that about 50% of patients entering the severe phase die within 7–10 days. This is not the fatality rate for all infections. Separate treated and untreated estimates were not established in the retrieved sources. |
| Reproduction number | unknown |
| Vaccine | A single dose provides lifelong protection; WHO reports immunity in 80–100% of recipients within 10 days and over 99% within 30 days. Some groups require medical assessment or should not receive it. |
| Treatment | Supportive care, including hydration and management of liver or kidney failure and other complications. No established specific antiviral treatment; sofosbuvir and TY014 are recommended only in research settings. |
| Reservoir | The virus is maintained in mosquito–primate transmission cycles in forest environments. |
| Endemic regions | Tropical Africa and the Americas. WHO classifies 27 African countries and 13 countries in Latin America as high-risk. |
Transmission
Yellow fever spreads through the bite of an infected mosquito. The main mosquito groups involved are Aedes, Haemagogus and Sabethes. They mostly bite during the day and occur in forest, household and settings between these environments. In forests, the virus circulates between mosquitoes and primates. People can become infected when they enter areas where this cycle is active. WHO links recent infections to forest exposure and spillover into rural communities with low vaccination coverage. Urban spread is a concern when suitable mosquitoes and many unvaccinated people are present. This is mosquito-mediated transmission, not evidence of direct spread through ordinary contact. Protective clothing, repellents and reducing mosquito breeding sites complement vaccination.
- Yellow fever WHO
- Yellow fever - Global WHO · 24 Jun 2026
Symptoms and severity
Symptoms usually begin 3–6 days after infection. Early signs include fever, headache, body aches, nausea, vomiting and weakness. These symptoms typically disappear within 3–4 days. About 15% of infected people develop severe illness, with returning high fever, yellowing of the skin and eyes, bleeding, organ failure or shock. WHO reports that about 50% of patients in this severe phase die within 7–10 days. That figure describes severe disease, not all infections, and the retrieved sources do not separate outcomes with and without treatment. Early symptoms overlap with several other diseases, so symptoms alone cannot confirm yellow fever. Blood testing is needed. Yellowing of the skin or eyes indicates severe disease and justifies hospitalization.
- Yellow fever WHO
Treatment and vaccines
There is no established specific antiviral treatment for yellow fever. Care focuses on hydration, fever management and treatment of complications, including liver and kidney failure. Antibiotics may be used for secondary bacterial infections, not to treat the virus itself. WHO recommends sofosbuvir and the antibody treatment TY014 only in research settings. Vaccination is the most effective prevention. A single dose provides lifelong protection, with no booster needed under WHO guidance. Immunity develops in 80–100% of recipients within 10 days and over 99% within 30 days. Vaccination is not suitable for everyone. Infants under nine months, people with certain immune disorders or severe egg allergies, pregnant people and adults over 60 need guidance appropriate to their circumstances.
- Yellow fever WHO
Where it occurs
Yellow fever occurs in tropical parts of Africa and the Americas, with most of the estimated global burden in Africa. WHO classifies 27 African countries and 13 Latin American countries as high-risk. Risk is not uniform within a country: forest exposure, local mosquito populations and vaccination coverage matter. In the Americas, WHO reported infections during 2026 in Bolivia, Brazil, Colombia, Ecuador, Peru and Venezuela. Recent African activity has included West and Central African countries. WHO’s 2026 global report describes no established local transmission cycles outside Africa and the Americas. However, introduction remains possible through travel, especially where suitable mosquitoes are present. Travel vaccination requirements and recommendations should therefore be checked for the specific destination and itinerary.
- Yellow fever WHO
- Yellow fever - Global WHO · 24 Jun 2026
- Yellow fever - WHO African Region WHO · 6 Nov 2026
Recent history
As of 2026-11-15, this site lists 111 archived yellow fever events from WHO notices since 1996 and major historical outbreaks. This counts archive entries, not necessarily separate epidemics. The retrieved archive shows repeated notices across Africa and the Americas, including Ghana, Nigeria, Uganda and Brazil. WHO’s 2025-05-16 Americas notice reported 212 confirmed cases and 85 deaths in its reporting period. Its 2026-06-24 global notice reported 79 confirmed infections in six American countries from 2026-01-01 to 2026-05-26. The newer 2026-11-06 African notice reported 67 confirmed cases and 18 deaths across nine countries through 2026-10-12. WHO assessed African regional risk as moderate and global risk as low on 2026-10-27. These regional totals have different reporting windows and should not be combined.
- Yellow fever - Region of the Americas WHO · 16 May 2025
- Yellow fever - Global WHO · 24 Jun 2026
- Yellow fever - WHO African Region WHO · 6 Nov 2026
What to watch
The most important warning signals are confirmed cases in previously unaffected areas, cross-border spread and mosquito-mediated transmission in towns or cities with low population immunity. Animal outbreaks can signal active forest circulation before more human cases are detected. Watch also for gaps in routine vaccination, delayed emergency campaigns, vaccine supply constraints and barriers to laboratory testing. WHO identifies rainfall, temperature, mosquito abundance and population movement as factors that can change risk. Unexpected direct human-to-human transmission would require investigation, but the retrieved sources describe mosquito-borne spread, not that pattern. The sources do not identify antiviral resistance as a current concern; no established specific antiviral treatment exists. Prompt confirmation and investigation of each case remain important, because reported cases can substantially understate an outbreak.
- Yellow fever WHO
- Yellow fever - Global WHO · 24 Jun 2026
- Yellow fever - WHO African Region WHO · 6 Nov 2026
Related outbreaks
- Yellow fever in Colombia elevated
- Yellow fever in Upper West Region, Ghana elevated